Posts

US lawmakers intensify scrutiny of Chinese clinical trials, raising industry concerns over cost and disruption

on

U.S. Launches Section 301 Investigation into Germany Over Drug Pricing and Unfair R&D Burden in 2026

on

Rare Disease Sales Projected to Exceed $400B by 2032 Despite Challenges, Driven by Small Molecule Resurgence

on

Trump Administration Pauses Pharmaceutical Tariffs to Negotiate Industry Agreements

on

Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries

on

Trump Administration May Exempt Some Pharma Products from Future Tariffs in Trade Policy Shift

on

UK Pharma Trade Group Calls for Overhaul of Government’s Life Sciences Investment Evaluation and Medicines Pricing Schemes

on

Trump Locks in 15% Pharmaceutical Tariff Rate for EU, Generic Drugs Exempted

on

Trump's Pharmaceutical Tariffs Materialize in New US-EU Trade Deal

on

FDA Investigates Patient Deaths Linked to Sarepta's Elevidys Gene Therapy for Duchenne Muscular Dystrophy

on

OpenAI Debuts HealthBench Dataset to Evaluate AI Models in Real-World Medical Scenarios

on

Citing tariffs, Illumina slashes guidance, confirms SEC's Grail investigation is closed

on

FDA delays decision date on Cytokinetics' heart drug to year-end in unusual safety program back-and-forth

on

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

on

U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs

on

AstraZeneca Shares Rise as China Investigation Impact Appears Limited

on